Responsiveness of plasma lipids and lipoproteins to plant stanol esters

American Journal of Cardiology

Volumn 96, Issue 1 SUPPL., 2005, Pages 23-28

  Cater, Nilo B ^a,b   Garcia Garcia, Ana Barbara ^a   Vega, Gloria Lena ^a   Grundy, Scott M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARGARINE; SIMVASTATIN; SITOSTANOL; STANOL ESTER;

ARTICLE; CLINICAL TRIAL; DIETARY INTAKE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ESTERIFICATION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 21244481731     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.03.016     Document Type: Article

References (18)

1. N.B. Cater Historical and scientific basis for the development of plant stanol ester foods as cholesterol-lowering agents Eur Heart J 1 1999 S36 S44
2. M.B. Katan, S.M. Grundy, P. Jones, M. Law, T. Miettinen, R. Paoletti Stresa Workshop Participants Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels Mayo Clin Proc 78 2003 965 978
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
4. G.L. Vega, P.T. Ma, N.B. Cater, N. Filipchuk, S. Meguro, A.B. Garcia-Garcia, S.M. Grundy Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome Am J Cardiol 91 2003 956 960
5. G.L. Vega, S.M. Grundy Quantitation of apolipoprotein B by chemical methods Methods Enzymol 263 1996 63 82
6. T.A. Luhr Use of a high-sensitivity C-reactive protein assay in evaluating cardiovascular disease risk Am Clin Lab 19 2000 20 21
7. T.A. Miettinen, R.S. Tilvis, Y.A. Kesaniemi Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population Am J Epidemiol 131 1990 20 31
8. A.M. Lees, H.Y. Mok, R.S. Lees, M.A. McCluskey, S.M. Grundy Plant sterols as cholesterol-lowering agents clinical trials in patients with hypercholesterolemia and studies of sterol balance Atherosclerosis 28 1977 325 338
9. M.A. Denke Lack of efficacy of low-dose sitostanol therapy as an adjunct to a cholesterol-lowering diet in men with moderate hypercholesterolemia Am J Clin Nutr 61 1995 392 396
10. P.W. Wilson, R.B. D'Agostino, D. Levy, A.M. Belanger, H. Silbershatz, W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
11. D.J. Jenkins, C.W. Kendall, A. Marchie, D.A. Faulkner, J.M. Wong, R. de Souza, A. Emam, T.L. Parker, E. Vidgen, K.G. Lapsley Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein JAMA 290 2003 502 510
12. C.W. Kendall, D.J. Jenkins A dietary portfolio maximal reduction of low-density lipoprotein cholesterol with diet Curr Atheroscler Rep 6 2004 492 498
13. S.N. Blair, D.M. Capuzzi, S.O. Gottlieb, T. Nguyen, J.M. Morgan, N.B. Cater Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy Am J Cardiol 86 2000 46 52
14. E. Stein, S. Stender, P. Mata, P. Sager, D. Ponsonnet, L. Melani, L. Lipka, R. Suresh, D. Maccubbin, E. Veltri Ezetimibe Study Group Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia efficacy and safety of ezetimibe co-administered with atorvastatin Am Heart J 148 2004 447 455
15. K.K. Ray, C.P. Cannon Intensive statin therapy in acute coronary syndromes clinical benefits and vascular biology Curr Opin Lipidol 15 2004 637 643
16. S.M. Grundy, G.L. Vega, M.E. McGovern, B.R. Tulloch, D.M. Kendall, D. Fitz-Patrick, O.P. Ganda, R.S. Rosenson, J.B. Buse, D.D. Robertson, J.P. Sheehan Diabetes Multicenter Research Group Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial Arch Intern Med 162 2002 1568 1576
17. E. Coban, R. Sari The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients Endocr Res 30 2004 343 349
18. H.E. Bays, L. Ose, N. Fraser, D.L. Tribble, K. Quinto, R. Reyes, A.O. Johnson-Levonas, A. Sapre, S.R. Donahue Ezetimibe Study Group A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia Clin Ther 26 2004 1758 1773